Effect of 24R,25-dihydroxyvitamin D3 in experimental diabetic rats.
The results are presented of a controlled study in male Wistar rats into the effects of 24R,25-dihydroxyvitamin D3 on blood glucose levels, bone calcium content and ADP-induced platelet aggregation in streptozocin-induced diabetes mellitus. Blood glucose levels were shown to be decreased by 10 micrograms/kg 24R,25-dihydroxyvitamin D3. The reduced bone calcium content associated with diabetes mellitus was returned to normal levels with both 1 and 10 micrograms/kg 24R,25-dihydroxyvitamin D3. It was also shown to exhibit dose-dependent anti-platelet activity. The data suggest that 24R,25-dihydroxyvitamin D3 might have potential as a mild therapeutic agent in the treatment of osteoporosis and platelet hyperactivity associated with diabetes mellitus.
Katoh
T
T
Biomedical Research Laboratories, Kureha Chemical Industry Co., Ltd, Tokyo, Japan.
Maeda
Y
Y
Yamato
H
H
Hirai
T
T
Fujii
T
T
Yoshino
F
F
Kodaira
T
T
Konai
Y
Y
D015650:24,25-Dihydroxyvitamin D 3; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001791:Blood Platelet Disorders / Q000188:drug therapy; D001842:Bone and Bones / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy*; D004100:Dihydroxycholecalciferols / Q000494:pharmacology*; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy; D010974:Platelet Aggregation / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains
D001786:Blood Glucose; D004100:Dihydroxycholecalciferols; D015650:24,25-Dihydroxyvitamin D 3; D002118:Calcium